Living Between Sickness and Health: Where Is the Human Genome Leading Us?

  • Amy Broadwater
  • Yashwant PathakEmail author


In recent years, much research has been done on genetic links to disease risk and development. The human genome contains thousands of SNPs or single nucleotide polymorphisms. These SNPs account for much of the variance between people; therefore, it makes sense that the SNPs could also reveal the variance in health between people. This chapter delves into common diseases that appear later in life and potential genetic risk factors for the diseases. Recent research has created ties between genome polymorphisms and cancer, cardiovascular health, and mental health. Identification of the polymorphisms could lead to a future of personalized medicine, where a patient’s genome would be used to assess risk of illness and prevent complications to the fullest extent. In some disease states, such as breast cancer, genomic research is already being used clinically to identify women at high risk of development. In other disease states, research is only just beginning to identify genetic loci that could be responsible for development. This chapter is meant to answer the following question: how much of our health can we control, and what role does genetic variation play in disease development?


  1. 1.
    PharmGKB (2016) Accessed Sept 2016.
  2. 2.
    SNPedia (2016) Accessed Sept 2016.
  3. 3.
    American Cancer Society (2016) Lifetime risk of developing or dying from cancer.
  4. 4.
    Common Cancer Types (2016) National Cancer Institute.
  5. 5.
    Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefGoogle Scholar
  6. 6.
    Chenh Y, Jiang T, Zhu M et al (2016) Risk assessment models for genetic risk predictors of lung cancer using two-stage replication for Asian and European populations. Oncotarget 8(33):53959–53967. E-published ahead of print. CrossRefGoogle Scholar
  7. 7.
    Xie K, Wang C, Qin N, Yang J et al (2016) Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk. Oncotarget 7(30):47966–47974., E-published ahead of print. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    El-Zein RA, Young RP, Hopkins RJ, Etzel CL (2012) Genetic predisposition to chronic obstructive pulmonary disease and/or lung cancer: important considerations when evaluating risk. Cancer Prev Res 5(4):522–527. CrossRefGoogle Scholar
  9. 9.
    Lee S, She J, Deng B, Kim J et al (2016) Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget 7(28):44211–44223. E-published ahead of print. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRefGoogle Scholar
  11. 11.
    Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22. CrossRefPubMedGoogle Scholar
  12. 12.
    Kleibl Z, Kristensen VN (2016) Woman at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast 28:136–144. CrossRefPubMedGoogle Scholar
  13. 13.
    Pelttari LM et al (2016) RAD51B in familial breast cancer. PLoS One 11(5):E0153788. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
  15. 15.
    Inherited Risk for Prostate Cancer. Memorial Sloan Kettering Cancer Center (2016).
  16. 16.
    Teerlink CC et al (2016) Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Hum Genet 135(8):923–938. E-published ahead of print. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hashemi M et al (2016) Association between ingle nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res 7(3):491–498. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Colorectal Cancer (2016) National Cancer Institute.
  19. 19.
    Inherited Risk for Colorectal Cancer. Memorial Sloan Kettering Cancer Center (2016).
  20. 20.
    Hahn MM et al (2016) The genetic heterogeneity of colorectal cancer predisposition-guidelines for gene discovery. Cell Oncol 39(6):491–510. E-published ahead of print. CrossRefGoogle Scholar
  21. 21.
    Zeng C et al (2016) Identification of susceptibility loci and genes for colorectal cancer risk. Gastroenterology 150(7):1633–1645. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    National Heart, Lung, and Blood institute (2016) What is Coronary Heart Disease? US Department of Health and Human Services.
  23. 23.
    Hrira MY, Chkioua L, Slimani A et al (2012) Hsp70-2 gene polymorphism: susceptibility implication in Tunisian patients with coronary artery disease. Diagn Pathol 7:88–92CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Liu D, Song J, Ji X, Liu Z, Cong M, Hu B (2016) Association of genetic polymorphisms on VEGFA and VEGFR2 with risk of coronary heart disease. Medicine (Baltimore) 95(19):e3413. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Souiden Y et al (2016) MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity. Biol Res 49:22. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hoeper MM, Bogaard HJ, Condliffe R et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–D50CrossRefPubMedGoogle Scholar
  27. 27.
    Liu L, Li Y, Tollefsbol TO (2008) Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 10:25–36PubMedPubMedCentralGoogle Scholar
  28. 28.
    Chelladurai P, Seeger W, Pullamsetti SS (2016) Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. Eur Respir Rev 25(140):135–140. CrossRefPubMedGoogle Scholar
  29. 29.
    Dean M, Hamon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007–1017. CrossRefPubMedGoogle Scholar
  30. 30.
    Cao XL, Yin RX, Huang F, Wu JZ, Chen WX (2016) Chromosome 9p21 and ABCA1 genetic variants and their interactions on coronary heart disease and ischemic stroke in a Chinese Han population. Int J Mol Sci 17(4):586. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lee TH et al (2016) Identification of PTCSC3 as a novel locus for large-vessel ischemic stroke: a genome-wide association study. J Am Heart Assoc 4(3):e003003. CrossRefGoogle Scholar
  32. 32.
    Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Investig 52(7):1544–1568. CrossRefPubMedGoogle Scholar
  33. 33.
    Ripatti P et al (2016) The contribution of GWAS loci in familial dyslipidemias. PLoS Genet 12(5):e1006078. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mayo Clinic Staff (2016) Depression (major depressive disorder). The Mayo Clinic, Rochester. Google Scholar
  35. 35.
    Anxiety and Depression Association of America (2016) Facts and Statistics. ADAA, Silver Spring. Google Scholar
  36. 36.
    Jelen AM et al (2015) The influence of C3435T polymorphism of the ABCB1 gene on genetic susceptibility to depression and treatment response in polish population – preliminary report. Int J Med Sci 12(12):974–979. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    National Institute of Mental Health (2016) Bipolar disorder among adults. NIMH, Bethesda. Google Scholar
  38. 38.
    Koefoed P, Andreassen O, Bennike B, Dam H, Djurovic S, Hansen T et al (2011) Combinations of SNPs related to signal transduction in bipolar disorder. PLoS One 6:e23812. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Mellerup E et al (2015) Combinations of genetic data present in bipolar patients, but absent in control persons. PLoS One 10(11):e0143432. CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Pihlstrom L, Axelsson G, Bjornara KA, Dizdar N, Fardell C, Forsgren L et al (2013) Supportive evidence for 11 loci from genome-wide association studies in Parkinson’s disease. Neurobiol Aging 34(6):1708 e7–1708 13. CrossRefGoogle Scholar
  41. 41.
    Shi C, Zheng Z, Wang Q, Wang C et al (2016) Exploring the effects of genetic variants on clinical profiles of Parkinson’s disease assessed by the unified Parkinson’s disease rating scale and Hoehn-Yahr stage. PLoS One 11(6):e0155758. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kumari U, Tan EK (2009) LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J 276(22):6455–6463. CrossRefPubMedGoogle Scholar
  43. 43.
    Kumaran R, Cookson MR (2015) Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson’s disease. Hum Mol Genet 24(R1):R32–R44. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ran C, Brodin L, Forsgren L, Westerlund M et al (2016) Strong Associatin between glucocerebrosidase mutations and Parkinson’s disease is Sweden. Neurobiol Aging 45:212.e5–212.e11. E-published ahead of print. CrossRefGoogle Scholar
  45. 45.
    DeMattos RB, Cirrito JR et al (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41:193–202CrossRefPubMedGoogle Scholar
  46. 46.
    US National Library of Medicine (2016) APOE: Apolipoprotein E. Genetics Home Reference.
  47. 47.
    Lambert JC, Heath S et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099CrossRefPubMedGoogle Scholar
  48. 48.
    Kang SS, Kurti A, Wojtas A, Baker KE et al (2016) Identification of plexin A4 as a novel clusterin receptor links two Alzheimer’s disease risk genes. Hum Mol Genet 25(16):3467–3475. E-published ahead of print. CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait. Arch Gen Psychiatry 60:1187–1192CrossRefPubMedGoogle Scholar
  50. 50.
    Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427CrossRefGoogle Scholar
  51. 51.
    Rohde PD et al (2016) Covariance association test (CVAT) identify genetic markers associated with schizophrenia in functionally associated biological processes. Genetics 203(4):1901–1913. E-Published ahead of print. CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lamantia AS (1999) Forebrain induction, retinoic acid, and vulnerability to schizophrenia: insights from molecular and genetic analysis in developing mice. Biol Psychiatry 46:19–30CrossRefPubMedGoogle Scholar
  53. 53.
    Park SJ, Lee JY et al (2015) Toll-like receptor 2 deficiency induces schizophrenia-like behaviors in mice. Sci Rep 5:8502. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.College of PharmacyUniversity of South Florida HealthTampaUSA

Personalised recommendations